"BioXcel Therapeutics, Inc. (BTAI) reported a Q2 loss that fell short of revenue expectations, which raises concerns about its financial stability amid ongoing clinical trials. However, the company is set to release topline data from its SERENITY Phase 3 trial, presenting a potential catalyst for future growth despite the current negative sentiment surrounding its performance."